Expression of GATA3 and Cytokeratin 14 in Urinary Bladder Carcinoma (Histopathological and Immunohistochemical Study)
DOI:
https://doi.org/10.3889/oamjms.2021.6740Keywords:
GATA3, Cytokeratin 14, Immunohistochemistry, Bladder carcinomaAbstract
BACKGROUND: Urothelial carcinoma (UC) with squamous differentiation (SD) is the most common histologic variant of bladder carcinoma and its presence is associated with poor prognosis which may need early radical cystectomy to avoid progression and recurrence. It is difficult to detect few foci of SD, especially nonkeratinizing or early switch from urothelial to squamous epithelium on only morphological basis. Combination of GATA3 and Cytokeratin 14 (CK14) could be helpful in differentiating pure UC, UC with SD and pure squamous cell carcinoma (SCC).
AIM: Assessment of GATA3 and CK14 expression in urinary bladder carcinoma and correlation with clinical and histopathological variables, for both diagnostic and prognostic purposes.
MATERIALS AND METHODS: Sixty cases of archived paraffin blocks of urinary bladder carcinoma were tested for GATA3 and CK14 expression by immunohistochemistry using a rabbit monoclonal antibody against human CK 14 and mouse monoclonal antibody against GATA3, respectively.
RESULTS: There is a significant correlation between GATA3 immunohistochemical expression and histological tumor subtypes of bladder carcinoma (p < 0.001), i.e. the GATA3 is a useful marker for urothelial origin especially in papillary UC. There is a significant correlation between GATA3 immunohistochemical expression and UC grade (p < 0.001). CK14 showed positive cytoplasmic staining in 9/14 (64.3%) cases of UC with SD and (13/13) (100%) cases of pure SCC and negative in 33/33(100%) cases of UC other than UC with SD. CK14 had sensitivity (64.3%) and specificity (100%) for areas of SD.
CONCLUSION: GATA3 is a specific immunohistochemical marker for urothelial origin. CK14 is a highly specific and sensitive immunohistochemical marker of squamous cell carcinoma.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;18(1):15. https://doi.org/10.3390/medsci8010015 DOI: https://doi.org/10.3390/medsci8010015
Elsharkawi F, Elsabah M, Shabayek M, Khaled H. Urine and serum exosomes as novel biomarkers in detection of bladder cancer. Asian Pac J Cancer Prev. 2019;20(7):2219-24. https://doi.org/10.31557%2FAPJCP.2019.20.7.2219 PMid:31350988 DOI: https://doi.org/10.31557/APJCP.2019.20.7.2219
Matulay JT, Narayan VM, Kamat A. Clinical and genomic considerations for variant histology in bladder cancer. Curr Oncol Rep. 2019;21:23. https://doi.org/10.1007/s11912-019-0772-8 PMid:30806832 DOI: https://doi.org/10.1007/s11912-019-0772-8
Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European association of urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. 2019;2(6):625-42. https://doi.org/10.1016/j.euo.2019.09.003 PMid:31601522 DOI: https://doi.org/10.1016/j.euo.2019.09.003
Lin X, Deng T, Wu S, Sharron X, Lin S, Wang D, et al. The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: A metaanalysis. World J Urol. 2019;38(2):323-33. https://doi.org/10.1007/s00345-019-02771-1 PMid:31011874 DOI: https://doi.org/10.1007/s00345-019-02771-1
Wang C, Yang S, Jin L, Dai G, Yao Q, Xiang H, et al. Biological and clinical significance of GATA3 detected from TCGA database and FFPE sample in bladder cancer patients. Onco Targets Ther. 2020;13:945-58. https://doi.org/10.2147/OTT.S237099 PMid:32099398 DOI: https://doi.org/10.2147/OTT.S237099
Agarwal H, Babu S, Rana C, Kumar, Singhai, Shankhwar SN, et al. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol. 2019;62(2):244-50. PMid:30971548 DOI: https://doi.org/10.4103/IJPM.IJPM_228_18
Robertson G, Kim J, Al-Ahmadie H, Bellmun J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-56. https://doi.org/10.1016/j.cell.2017.09.007 PMid:30971548 DOI: https://doi.org/10.1016/j.cell.2017.09.007
Jung M, Jang I, Kim K, Moon KC. CK14 expression identifies a basal/squamous-like type of papillary non-muscle-invasive upper tract urothelial carcinoma. Front Oncol. 2020;10:623. http://doi:10.3389/fonc.2020.00623 PMid:32391279 DOI: https://doi.org/10.3389/fonc.2020.00623
El-Nashar A, Sotohy TM, Mohammad EM, Mahmoud SF, Badawy A. The use of desmocollin-2 and cytokeratin-14 for detection of squamous cell carcinoma and squamous differentiation in urothelial carcinoma. Med J Cairo Univ. 2016;849(1):387-94.
Moch H, Humphrey PA, Ulbright TM, Reuter VE. Tumors of the urinary tract. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. Lyon: IARC; 2016. p. 78. https://doi.org/10.1016/j.eururo.2016.02.029 DOI: https://doi.org/10.1016/j.eururo.2016.02.029
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours. Eur Urol. 2016;70(1):106-19. https://doi.org/10.1016/j.eururo.2016.02.028 PMid:26996659 DOI: https://doi.org/10.1016/j.eururo.2016.02.028
American Cancer Society. Last Medical Review. Atlanta, Georgia: American Cancer Society; 2019.
Chang A, Amin A, Gabrielson E, Illei P, Roden RB, Sharma R, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinoma of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36(10):1472-6. https://doi.org/10.1097/pas.0b013e318260cde7 PMid:22982890 DOI: https://doi.org/10.1097/PAS.0b013e318260cde7
Moselhy AA, Aiad HA, El Rebey HS, Mahmoud SE. Immunohistochemical expression of cytokeratin 14 and association with the extent of squamous differentiation in urothelial carcinoma. Menoufia Med J. 2018;31:826-33.
Mohammed KH, Siddiqui MT, Cohen C. GATA3 immunohistochemical expression in invasive urothelial carcinoma. Urol Oncol. 2016;34(10):432.e9-13. https://doi.org/10.1016/j.urolonc.2016.04.016 PMid:27241168 DOI: https://doi.org/10.1016/j.urolonc.2016.04.016
Wang CC, Tsai YC, Jeng YM. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle invasive bladder cancer. PLoS One. 2019;14(8):e0221785. https://doi.org/10.1371/journal.pone.0221785 PMid:31469885 DOI: https://doi.org/10.1371/journal.pone.0221785
Liang Y, Heitzjman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014;45(7):1466-72. https://doi.org/10.1016/j.humpath.2014.02.023 PMid:24745616 DOI: https://doi.org/10.1016/j.humpath.2014.02.023
Helmy NA, Khalil HK, Kamel NN, AboelFadl DM. Role of GATA3, CK7, CK20 and CK14 in distinguishing urinary bladder squamous cell carcinoma and urothelial carcinoma with squamous differentiation. Egypt J Pathol. 2015;35(2):133-8. https://doi.org/10.1097/01.XEJ.0000472878.82311.73 DOI: https://doi.org/10.1097/01.XEJ.0000472878.82311.73
Miyamoto H, Izumi K, Yao JL, Li Y, Yang Q, McMahon LA, et al. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Hum Pathol. 2012;43(11):2033-40. https://doi.org/10.1016/j.humpath.2012.02.011 PMid:22607700 DOI: https://doi.org/10.1016/j.humpath.2012.02.011
Kamel NA, Abdelzaher E, Elgebaly O, Ibrahim SA. Reduced expression of GATA3 predicts progression in non-muscle invasive urothelial carcinoma of the urinary bladder. J Histotechnol. 2020;43(1):21-8. https://doi.org/10.1080/01478885.2019.1667126 PMid:31551051 DOI: https://doi.org/10.1080/01478885.2019.1667126
Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H. GATA3 in the urinary bladder: Suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res. 2014;4(5):461-73. PMid:25232488
Abdullah W, Kerbel H, Husseini R. Applying gata3 in differentiating urothelial carcinoma from prostatic adenocarcinoma: An immunohistochemical study. Asian J Pharm Clin Res. 2018;11(12):292-5. https://doi.org/10.22159/ajpcr.2018.v11i12.28232 DOI: https://doi.org/10.22159/ajpcr.2018.v11i12.28232
Gulmann C, Paner GP, Parakh RS, Hansel DE, Shen SS, Ro JY, et al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol. 2013;44(2):164-72. https://doi.org/10.1016/j.humpath.2012.05.018 PMid:22995333 DOI: https://doi.org/10.1016/j.humpath.2012.05.018
Hammam O, Wishahi M, Khalil H, Ganzouri H, Badawy M, Elkhquly A, et al. Expression of cytokeratin 7, 20, 14 in urothelial carcinoma and squamous cell carcinoma of the Egyptian urinary bladder cancer. J Egypt Soc Parasitol. 2014;44(3):733-40. PMid:25643514 DOI: https://doi.org/10.21608/jesp.2014.90369
Jangir H, Nambirajan A, Ranjit AS, Sahoo K, Dinda AK, Nayak B, et al. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20. Ann Diagn Pathol. 2019;43:151397. https://doi.org/10.1016/j.anndiagpath.2019.08.001 PMid:31494492 DOI: https://doi.org/10.1016/j.anndiagpath.2019.08.001
Downloads
Published
How to Cite
License
Copyright (c) 2021 Nora Elzohery, Nourelhoda Sayed Ismael, Rasha Ahmed Khairy, Somia A. M. Soliman (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
